An interesting factor to assess would have been APOE ε4-status, as APOE ε4-carriership might modulate the relationship between sleep disruption and AD [75]; however, our ethical review board at the time did not allow individual APOE genotype determination in this study. The gene discussed is APOE; the disease is Alzheimer disease.